Objectives: To describe the pathological characteristics after neoadjuvant chemotherapy
(macroscopic disease, Chemotherapy Response Score – CRS at the ovary and omentum, vascular
invasion, and uterine invasion) and to analyze the association between CRS and selected clinical
characteristics Patients and Methods: A cross-sectional descriptive study was conducted on 78
patients with advanced ovarian cancer who received neoadjuvant chemotherapy followed by
maximal cytoreductive surgery at K Hospital – Tan Trieu facility, from January 2025 to March
2026. Results: The rate of no gross residual disease was 16.7%; residual disease ≤1cm
accounted for 41.0% and >1cm for 42.3%. A CRS3 score (complete/near-complete response)
was achieved in 21.8% of patients at both the ovary and omentum. Vascular invasion was
recorded in 7.7% and uterine invasion in 26.9% of patients. Regarding the association with CRS:
patients ≥60 years old had a higher CRS3 rate than those <60 years old (26.8% vs 16.2%), but
the difference was not statistically significant (p>0.05); stage IV patients had a higher CRS3 rate
than stage III patients (25.8% vs 19.1%), also without statistical significance (p>0.05); patients
whose CA125 level normalized completely after chemotherapy had a significantly higher CRS3
rate than those with incomplete decrease (92.1% vs 65%, p=0.004); the addition of Bevacizumab
to the chemotherapy regimen did not increase the CRS3 rate (p>0.05). Conclusion: Most
patients in this study still had residual gross disease after neoadjuvant chemotherapy, and the rate
of omental CRS3 was moderate. The degree of CA125 decline after chemotherapy was the only
factor significantly associated with the likelihood of achieving CRS3, whereas age, disease stage,
and the addition of Bevacizumab showed no significant association.